Premium
High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory H odgkin lymphoma ( HL )
Author(s) -
Wannesson B.,
Remaggi G.,
Intile D.,
Ferrari L.,
Cruset S.,
Fernández I.,
Miodosky M.,
Cugliari M.S.,
Bordone J.,
Pavlovsky M.A.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2439_61
Subject(s) - brentuximab vedotin , medicine , bendamustine , refractory (planetary science) , regimen , common terminology criteria for adverse events , gastroenterology , surgery , oncology , adverse effect , lymphoma , rituximab , hodgkin lymphoma , physics , astrobiology